Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Employment agrmnt
Quarterly results
Director departure
Appointed director
Notes underwriting agrmnt

SANUWAVE Health, Inc. (SNWV) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 425 Form 425 - Prospectuses and communications, business combinations:
10/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "SANUWAVE Health, Inc. , a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the third quarter of 2023 are expected to be in the range of $4.7 to $4.9 million."
10/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
09/29/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
08/24/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/23/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/23/2023 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among SEP Acquisition Corp., SEP Acquisition Holdings Inc., and SANUWAVE Health, Inc",
"Form of Voting Agreement, by and among SEP Acquisition Corp., SANUWAVE Health, Inc., and the stockholder of SANUWAVE Health, Inc. party thereto",
"Sponsor Voting Agreement, by and among Mercury Sponsor Group I LLC, SEP Acquisition Corp., and SANUWAVE Health, Inc",
"Form of Lock-Up Agreement, by and between SEP Acquisition Corp. and the stockholder of SANUWAVE Health, Inc. party thereto",
"Exhibit 99.1"
08/22/2023 SC 13D/A MANCHESTER MANAGEMENT CO LLC reports a 11.7% stake in Sanuwave Health, Inc.
08/11/2023 8-K Quarterly results
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 4 MANCHESTER MANAGEMENT CO LLC (Director by Deputization) has filed a Form 4 on SANUWAVE Health, Inc.
Txns: Converted 71,875,000 shares @ $0.04, valued at $2.9M
Converted 10,442,806 shares @ $0.04, valued at $417.7k
Converted options to buy @ $0.04, valued at $0
Converted options to buy @ $0.04, valued at $0
08/08/2023 3 Walko Andrew (President) has filed a Form 3 on SANUWAVE Health, Inc.
08/07/2023 D Form D - Notice of Exempt Offering of Securities:
07/31/2023 8-K Quarterly results
07/27/2023 SC 13D/A MANCHESTER MANAGEMENT CO LLC reports a 13.1% stake in Sanuwave Health, Inc.
07/27/2023 4 MANCHESTER MANAGEMENT CO LLC (Director by Deputization) has filed a Form 4 on SANUWAVE Health, Inc.
Txns: Acquired options to buy @ $0
Acquired 12,500,000 warrants @ $0
Acquired 1,875,000 warrants @ $0
07/26/2023 8-K Quarterly results
07/19/2023 8-K Quarterly results
06/30/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
06/29/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Fourth Amendment to Note and Warrant Purchase and Security Agreement, by and among the Company, the noteholder party thereto and NH Expansion Credit Fund Holdings LP, as agent"
05/16/2023 D Form D - Notice of Exempt Offering of Securities:
05/12/2023 8-K Quarterly results
Docs: "Sanuwave announces Q1 2023 financial results"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/03/2023 8-K Quarterly results
Docs: "Recent Developments and Upcoming Events"
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/31/2023 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/31/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
01/12/2023 4 MANCHESTER MANAGEMENT CO LLC (Director by Deputization) has filed a Form 4 on SANUWAVE Health, Inc.
Txns: Disposed of options to buy @ $0.04, valued at $0
Disposed of 20,000,000 warrants @ $0
11/18/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/14/2022 8-K Quarterly results
Docs: "Press Release",
"Eden Prairie, MN, August 15, 2022 - SANUWAVE Health, Inc. a leading provider of next-generation wound care products, reported financial results for their second quarter, ending June 30, 2022, with the SEC on Friday, August 12, 2022. The Company will host a live conference call on Tuesday August 16, 2022, at 12:30 to provide a business update . Quarter Highlights: - Over 50 systems placed to treat wounds o 100% increase from the 25 systems placed Q2 2021 - Over 40,000 wound treatments administered o Up from 31,000 treatments administered Q2 2021 - Successfully completed MDSAP audit - Transitioned company from Suwanee GA to Eden Prairie MN - Became current on SEC filings - Launched Cosmetic and Orthopedics verticals with initial sales in each “Our key ENERGY FIRST products, dermaPACE® and Ul..."
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy